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Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in
adults. Although FEV1 remains the most important physiologic indicator of the severity of
airflow obstruction in COPD, its predictive value for mortality is weak when it is higher than
50% of predicted. Furthermore, other easily obtainable clinical variables predict mortality
better than the FEV1 in COPD patients with a wide range of airflow limitation. Chief among
these predictors are functional dyspnea, exercise capacity, and the body mass index (BMI),
although emerging research suggests a potential role for biomarker profiles in outcome
predictions. The validated multidimensional BMI (B), degree of airflow obstruction as ex-
pressed by the FEV1 (O), dyspnea with the modified medical research council (D), and exer-
cise (E) measured with the 6 min walk or BODE index encompasses the predictive validity of
the best of these variables into a single surrogate measure of disease severity and survival.
This article reviews these predictors of mortality in COPD.
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fourth leading cause of death worldwide1 and it will
become the third leading cause of death worldwide by
2020.2,3 This increasing mortality is attributed to the
smoking epidemic and the aging of the world population.
The prevalence of COPD has increased as mortality from
heart attacks and strokes, both of which share a common
risk factor with COPD (ie, cigarette smoking), has
decreased.4 In 2004, the United States ranked third highest
among 18 industrialized countries in COPD mortality for
females and fourth highest for males.5
Although the hallmark feature of COPD is airflow limi-
tation resulting from chronic bronchitis or emphysema,
COPD is often accompanied by multiple comorbidities that
lead to a spiral of decline, with an increased risk for
mortality. The extent to which specific comorbidities and
symptoms may be used to predict COPD mortality is
unclear. This article reviews potential predictors of
mortality in COPD.e 1 COPD Results from Inflammation. Legend: Airway inflam
increased numbers of macrophages and CD8þ T-lymphocy
okines (e.g. interleukin [IL]-8), cytokines (e.g. tumor necros
x metalloproteinase) that are instrumental in producing a c
364:985.6 (no permissions required).Forced expiratory volume in 1 second
COPD is a complex disease with many inflammatory path-
ways that initiate and potentiate the disease process
(Fig. 1). Neutrophils, macrophages and CD8þ T-lympho-
cytes are the key inflammatory cell types involved in
COPD.
These cells release the reactive oxygen species (ROS),
chemokines (e.g. interleukin [IL]-8), cytokines (e.g. tumor
necrosis factor [TNF]-a) and proteases (e.g. neutrophil
elastase and matrix metalloproteinase) that are instru-
mental in producing a chronic inflammatory state.6,7
The ongoing inflammatory process leads to enlargement
of the alveolar spaces, fibrosis, destruction of the lung
parenchyma, loss of elasticity and small airways obstruc-
tion (obstructive bronchiolitis). Mucus hypersecretion is
a prominent feature of COPD. In contrast to asthma, airway
hyper-responsiveness is not a commonly prevalent feature
of COPD.6,7 Notably, histological studies reveal that evenmation in COPD is characterized by a neutrophilic inflammation
tes. These cells release the reactive oxygen species (ROS),
is factor [TNF]-a) and proteases (e.g. neutrophil elastase and
hronic inflammatory state.6,7 Source: Barnes, Hansel. Lancet
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COPD which will obstruct the airways as long as 20 years
after smoking cessation.8
Fletcher and Peto’s landmark 1977 study9 reported
a relationship between airflow obstruction and survival in
a study of more than 2700 men who were followed for 20 to
25 years. This study reported that in patients who had COPD,
the risk of death was strongly correlated with the degree of
measured FEV1 at the initial study survey. Longitudinal data,
however, revealed overlap in the rate of decline of FEV1
between patients with COPD and control subjects so that
individual values of FEV1 are not good predictors of outcome.
Since this early spirometry research, several studies have
confirmed the statistically significant but not strong rela-
tionship between FEV1 and mortality.
10e13 In spite of this
weak relationship, the risk of death in patients with COPD is
still gradedwith the use of this single physiological variable.9
There are several other problems with using the FEV1 as
an outcome measure in clinical trials of COPD. First and
foremost, FEV1 cannot change in patients whose disease
is characterized as poorly reversible. Indeed, it is going to
be very difficult to alter the rate of decline of FEV1 in
studies that select patients who are unresponsive to
bronchodilators. Yet most studies have focused on this
largely unachievable physiological outcome. Second,
FEV1 values do not fully express the complexity of COPD and
all of its manifestations. Other easily obtainable clinical
variables predict mortality better than FEV1 in COPD
patients.
An appreciation of the mechanisms contributing to the
progression of COPD will help to illuminate outcome
predictors. We have learned over the past 15 years that
people with COPD have an increased prevalence of lung
cancer, myopathy, osteoporosis, anemia, coronary artery
disease, anxiety, and depression.14 Whether these common
comorbidities are part of a spillage of disease from the
lungs to other body systems or whether they are separate
components of a systemic inflammation is a matter of
ongoing debate. Many different studies performed over the
past decade suggest that COPD is associated with low-grade
systemic inflammation. A meta-analysis of these studies15
confirms that patients with stable COPD maintain increased
numbers of leukocytes (some of them with an activated
phenotype) and increased levels of acute phase response
proteins (C-reactive protein [CRP] and fibrinogen) and
cytokines like IL-6 and TNF.15
Irrespective of the debate surrounding the origins of
COPD comorbidities, their role in the clinical course of
COPD is receiving increasing attention. A recent prospec-
tive study of 955 patients with COPD for approximately 5
years documented comorbid conditions for which patients
had received treatment. There were 84 comorbidities
requiring treatment. Logistic regression analysis using
mortality as the dependent variable identified lung cancer,
nicotine addiction, depression, obesity, coronary artery
disease, congestive heart failure, atrial fibrillation,
peripheral vascular disease, diabetes mellitus, gastro-
esophageal reflux disease, prostate cancer, obstructive
sleep apnea, and pulmonary hypertension as the variables
with independent association with hospitalization and
survival. The total number of comorbidities correlated with
hospitalizations (rZ 0.28, p< 0.001).16Causes of mortality in COPD
Findings surrounding causes of mortality in COPD vary,
depending on the population studied. The Lung Health
Study17 was a randomized clinical trial of smoking cessation
and inhaled bronchodilator therapy (ipratropium) in 5887
smokers 35 to 60 years of age who did not consider them-
selves ill, had little evidence of other disease, but had mild
to moderate airway obstruction. During 14 years of follow-
up, mortality was relatively low at approximately 12%. The
most common causes of mortality in this cohort were
cancer (33%) and cardiovascular disease (22%); respiratory
disease accounted for only 8% of deaths. These findings led
to the widespread assumption that the primary cause of
death in patients with COPD is heart disease.
In patients with more severe COPD, however, a very
different mortality profile emerges. A pooled analysis18 of
individual patient data from seven randomized trials
involving 5085 patients with stable COPD was performed,
comparing the effects of inhaled corticosteroids and
placebo. Among the 4% of patients who died during 26
months of follow-up, the leading cause of mortality was
respiratory disease, as opposed to cardiovascular causes
(34% and 30%, respectively). Cancer and other causes
accounted for 21% and 15% of mortalities, respectively.
These findings were confirmed by the TORCH study,19 which
also reported respiratory illness as the leading cause of
mortality (35%), followed by cardiovascular disease (27%),
cancer (21%), other (10%), and unknown (7%).19
Exercise capacity as a predictor of mortality
Several systemic manifestations that accompany COPD can
signal an increased risk for mortality. Recognizing these
manifestations allows for a more comprehensive assess-
ment of disease severity and helps clinicians to make
informed prognoses in patients with a wide range of airflow
limitation.
Exercise capacity is one of the most important prognostic
predictors. The spiral of decline in COPD is characterized by
progressively decreased exercise capacity and impaired
physical functioning. Exercise capacity reflects both respi-
ratory and non-respiratory manifestations of COPD and also
indicates the extent to which the pulmonary and cardiovas-
cular systems can coordinate to supply oxygen to the rest of
the body. COPD patients have been shown to have an accel-
erated loss of aerobic capacity (VO2max) which impacts on
overall physical functioning. Whether exercise capacity can
predict mortality has been the subject of several studies. A
long-term study of 6213 men revealed that after adjustment
for age, the peak exercise capacity was the strongest
predictor of the risk of death among both normal subjects
and those with cardiovascular disease.20 In the setting of
COPD specifically, a study of 144 patients who were followed
for 5 years reported 31 deaths. VO2max was shown to be the
best predictor of mortality, independent of FEV1 and patient
age.21 In a study by Pinto-Plata and colleagues,22 the
6 minute walk distance test (6MWD) was determined in 198
patients with severe COPD. Over a 2-year period, survival
increased progressively with increases in the 6MWD. Patients
unable towalk 100 mhad amortality rate approaching 90% at
776 B.R. Celli1 year. Yet thosewith similarly impaired airflow (asmeasured
by their FEV1) who were able to walk more than 400 m had
significantly higher survival (p< 0.0001). The study demon-
strated that exercise capacity was a better predictor of
mortality than both FEV1 and body mass index (BMI).
22 From
a clinical standpoint, a quick exercise capacity test for
a variety ofmedical problems, be it pulmonary hypertension,
congestive heart failure, or interstitial pulmonary fibrosis,
will help the physician to assess patient status and adopt
appropriate interventions.Multidimensional risk assessment
Given the systemic consequences of COPD, use of
a composite index to assess prognosis may provide a more
comprehensive way to evaluate COPD. The predictive value
of numerous variables were evaluated in a prospective
study of 207 patients with COPD.4 The study assessed age,
gender, smoking history in packs per year, functional vital
capacity, FEV1, dyspnea measured with the modified
Medical Research Council dyspnea scale, BMI, functional
residual capacity, inspiratory capacity, hematocrit, and
albumin level. At 1 year, the investigators identified four
variables that were most predictive of mortality risk: BMI,
FEV1, dyspnea, and exercise capacity. These variables were
incorporated into the BODE index, a multifactorial 10-point
staging scale that predicts risk of death in patients with
COPD, a multidimensional assessment scale. Given the
complex pathophysiology of COPD, the development of
a multidimensional index e such as the BODE index e
provides a means of classifying patients with COPD that also
correlates with their prognosis. The individual components
of the BODE index incorporate the pulmonary as well as the
systemic effects seen in patients with COPD. The BODE
index was then validated prospectively in 625 COPD
patients who were evaluated every 6 months for at least 2
years. Each quartile increase in the BODE index score
correlated to an increase in mortality risk. Patients with
a BODE index in the quartile 4 (bode index score of 7e10)
had a mortality rate of 80% at 52 months.4 When shown in
relation to the severity of COPD according to the staging
system of the American Thoracic Society in place in 2004,
the C statistic of the ability of the BODE index to predict
the risk of death was 0.74, as compared with a value of 0.65
with the use of FEV1 alone.
23 Ongoing follow-up of this
initial study cohort and new patients continues to support
the prognostic value of the BODE index.
Imfeld and colleagues24 investigated whether the BODE
index is able to predict survival after lung volume
reduction surgery (LVRS) in a 40-month retrospective
study of 186 patients with severe COPD. BMI, pulmonary
function, 6MWD, and the modified Medical Research
Council dyspnea score were assessed before and 3 months
after LVRS, and the BODE index was calculated. The mean
BODE index decreased from 7.2 1.6 preoperatively to
4.0 2.0 at 3 months after LVRS (p< 0.001). The post-
operative BODE, but not the preoperative BODE, corre-
lated with survival. A decrease to a lower BODE score
class was associated with a reduced mortality (hazard
ratio, 0.497, 95% confidence interval, 0.375e0.659;
p< 0.001). Further, the BODE index was found to be morepredictive of mortality than the FEV1. These findings were
confirmed by a comprehensive analysis of the data from
the National Emphysema Therapy Trial (NETT).25 This
study randomized patients to medical treatment or to
lung volume reduction surgery and followed them for over
5 years. A modified BODE score was calculated using the
San Diego dyspnea scale instead of the original modified
MRC scale and calculated in the same manner as the
original BODE score. The change in BODE index measured
at 6 months after randomization predicted survival at 2
and 5 years demonstrating the predictive power of BODE
and equally important its possible role as a surrogate
marker of response to therapy.
Inspiratory fraction
Static lung hyperinflation has important clinical conse-
quences in patients with chronic obstructive pulmonary
disease. A recent study26 suggests a role for the inspiratory-
to-total lung capacity ratio or ‘‘inspiratory fraction’’ (inspi-
ratory capacity(IC)/total lung capacity (TLC)) as a measure
of functional reserve and a predictor of mortality. In this
study of 689 patients who had COPD, IC/TLC was found to be
an important independent predictor of increased mortality.
The IC/TLC also predicts exercise capacity27 and has impor-
tant influence on cardiac function during exercise.28
Exacerbations
Exacerbations of COPD are a major cause of morbidity,
mortality and hospital admission, but there is currently no
widely accepted definition of what constitutes an exacer-
bation of COPD.29,30 In an attempt to correlate patient
characteristics during acute exacerbation and length of
survival, Connors and colleagues31 conducted a prospective
analysis of a cohort of 1,016 adult patients who were
admitted to hospitals due to COPD exacerbations. Although
only 11% of the patients died during the hospital stay, the
60-day, 180-day, 1-year, and 2-year mortality was high
(20%, 33%, 43%, and 49%, respectively). Survival time was
independently related to multiple factors, including illness
severity, BMI, age, and other variables. Soler-Catalunya
et al. have clearly shown in a cohort of patients with COPD
that outcomes, including survival, are related to the pres-
ence, frequency and intensity of exacerbations with
patients having no exacerbations manifesting better
survival than those with more frequent visits to the emer-
gency room or hospitalizations.32 The same authors have
demonstrated that the addition of exacerbations to the
BODE may improve its predictive capacity.33
Biomarkers
The pathobiological processes that manifest in the lungs and
elsewhere in patients with COPD could be associated with
systemic biomarker levels detectable in the systemic circu-
lation. There has been increasing interest in identifying
pulmonary biomarkers of COPD to predict pathogenic
processes and pharmacological responses. Potential
biomarker sources include bronchial biopsies and bron-
choalveolar lavage, which are highly invasive and thus
Predictors of mortality in COPD 777difficult to repeat. Exhaled gases and breath condensate are
considerably less invasive, but results are highly variable.
Induced sputum has provided useful information about
inflammation and infection. Serum is easily obtainable, but
predictive markers have yet to be substantiated. A compre-
hensive review of the literature on pulmonary biomarkers in
COPD34 concludes that though many have been described,
none are in use, and more research is needed.
Limited data are available from histologic data from
a study of the antiinflammatory effects of salmeterol/flu-
ticasone propionate in COPD.35 Study subjects underwent
bronchial biopsies and sputum analysis at baseline and at
the end of the study to determine change in the numbers of
CD8þ and CD68þ cells/mm2 in biopsy specimens and
sputum neutrophils. Treatment was shown to reduce CD8þ
cells and sputum neutrophils. Another study profiled gene
expression of human lung tissue from smokers with severe
emphysema and identified 102 genes that accurately
distinguished severe emphysema from other lung tissue.36
However, the clinical value of these findings has not yet
been demonstrated. There is little information about how
these and other biomarkers relate to disease progression,
severity, or response to therapy. Nor is there any evidence
to support a relationship between biomarkers and the
extrapulmonary manifestations of COPD.
Histological analysis within the setting of oncology has
been more conclusive. A study of gene expression in tissue
from lung cancer specimens37 revealed 16 genes that
correlated with survival among patients. When five genes
were selected for further analysis, they were found to
independently predict relapse-free and overall survival.
Further, response to chemotherapy was associated with the
presence of the 5 genes. The study clearly links biomarkersPA
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its entirety from Pinto-Plaza et al.42 (permission to reproduce requto both disease outcome and therapeutic response in lung
cancer; unfortunately, there are no comparable findings in
the COPD literature.
A systematic review15 of studies reporting on the rela-
tionship between FEV1 or forced vital capacity (FVC) and
levels of various systemic inflammatory markers revealed an
association between CRP and reduced lung function. A
subsequent editorial38 commented on three additional
studies that demonstrated an inverse linear relationship
between FEV1 and CRP. The clinical utility of these findings,
however, is questionable. An elevated CRP is nonspecific
since it suggests anynumberof healthproblems.WhyuseCRP
as amarker of impaired lung function when FEV1 is easily and
non-invasively obtainable and is more specific to the
pulmonary system? Markers are of clinical significance only
when their change predicts a change in health outcomes.
Recent research has attempted to bridge this gap. An
8-year follow-up of 1302 participants from the Copenhagen
City Heart Study who were identified as having airway
obstruction (defined as FEV1/FVC less than 0.7) revealed
higher baseline serum levels of CRP in participants who
were subsequently diagnosed with COPD.39 A baseline CRP
value of more than 3 mg/L in this population of patients
with airway obstruction was predictive of COPD hospitali-
zation and death. A multifactorial analysis including sex,
age, FEV1% predicted, tobacco consumption, and ischemic
heart disease showed an increase of equivalent hazard
ratios for COPD hospitalization and COPD death of 1.4
(1.0e2.0) and 2.2 (1.2e3.9), respectively. However,
a separate analysis of our own BODE study cohort (NZ 218)
did not duplicate these findings. Mortality rates were
comparable among patients with CRP levels higher than
3 mg/L and those with levels lower than 3 mg/L.40 FromTG
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778 B.R. Cellia clinical perspective, therefore, CRP appears to be less
useful than FEV1, BMI, and 6-minute walking distance.
Recently, there has been some use of high-density
microarray technology to systematically define the serum
protein expression profile in patients with COPD.41,42 The
most recent of these studies42 explored the relationship
between a selected subset of 24 biomarkers with clinically
important outcome variables in COPD, including lung
function, the BODE index and its components, and the
frequency of exacerbations. The biomarkers were selected
from clusters statistically associated with the diagnosis of
COPD and thought to have known or potential significance
in the pathobiology of COPD.
The study identified a biomarker profile (Fig. 2) char-
acteristic of patients with COPD. The study further
demonstrated an association between the level of selected
biomarkers and lung function, the degree of airflow limi-
tation and DLCO, a marker of lung tissue destruction. The
study also showed a correlation between the expression of
the serum biomarkers and clinical manifestations of COPD
represented by functional capacity, the BODE index, and
exacerbation rates.
Conclusions
Intriguing as these findings are, I concur with the words of
one of the esteemed forefathers of modern medicine, Sir
William Osler, who said ‘‘If it were not for the great vari-
ability among individuals, medicine might as well be
a science and not an art.’’ The predictive value of specific
biomarker profiles in individuals with COPD, in my opinion,
remains uncertain. Although biological marker discovery is
an intriguing research topic and may help us identify novel
therapeutic approaches, it is complex and challenged by
technological problems and biological noise which still need
to be addressed. Clinical physiological markers, incorpo-
rated into the BODE index and other multidimensional
staging tools, may be valuable not only in the assessment of
severity and progression of disease, but also in evaluating
the response to medical interventions.
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